Credit Suisse Ag Summit Therapeutics Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 111,078 shares of SMMT stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111,078
Previous 108,350
2.52%
Holding current value
$1.99 Million
Previous $282,000
62.77%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$437 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$196 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$141 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$97.3 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$62.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...